1-10 of 10
Erika Szabo
Close
Sort by
Journal Articles

Real-World Healthcare Resource Utilization in Patients with Indolent Non-Hodgkin's Lymphoma: Differences between Patients Treated First-Line with Ibrutinib or Bendamustine + Rituximab

Debra Irwin, Lu Zhang, ScD, Kathleen Wilson, MPH, Gerard Hoehn, PhD, Erika Szabo, Boxiong Tang, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3549.
https://doi.org/10.1182/blood-2018-99-113093
Published: 2018
Journal Articles

Assessing the Need for a Biosimilar: A Systematic Literature Review of the Treatment Burden of Rituximab in Hematological Malignancies

Elizabeth James, Holly Trautman, Gerard Hoehn, PhD, Erika Szabo, Boxiong Tang, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5908.
https://doi.org/10.1182/blood-2018-99-110953
Published: 2018
Journal Articles

Real-World Healthcare Resource Utilization in Patients with Chronic Lymphocytic Lymphoma: Differences between Patients Treated with Ibrutinib or Bendamustine + Rituximab

Debra Irwin, Lu Zhang, ScD, Kathleen Wilson, MPH, Gerard Hoehn, PhD, Erika Szabo, Boxiong Tang, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3548.
https://doi.org/10.1182/blood-2018-99-112626
Published: 2018
Journal Articles

Comparative Cost-Efficiency Analysis of Granulocyte Colony-Stimulating Factors for Use in Chemotherapy Patients in the United States

Elizabeth James, Holly Trautman, Erika Szabo, Boxiong Tang, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4667.
https://doi.org/10.1182/blood.V130.Suppl_1.4667.4667
Published: 2017
Journal Articles

Budget Impact Analysis of Switching Chemotherapy Patients Using Granulocyte Colony-Stimulating Factors (G-CSFs) from Pegfilgrastim to Short-Acting G-CSFs in the United States

Elizabeth James, Holly Trautman, Erika Szabo, Boxiong Tang, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4668.
https://doi.org/10.1182/blood.V130.Suppl_1.4668.4668
Published: 2017
Journal Articles

Real-World Characteristics of CLL Patients Receiving Front-Line Therapy, Using the Flatiron Health Database

Boxiong Tang, MD PhD, Erika Szabo, Jifang Zhou, MD, Jerry Wu, Danielle M. Brander, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4671.
https://doi.org/10.1182/blood.V130.Suppl_1.4671.4671
Published: 2017
Journal Articles

Length of Stay for Hospitalized Patients Treated with Ibrutinib or Bendamustine First-Line Therapy for Treatment of Chronic Lymphocytic Leukemia

Debra Irwin, Erika Szabo, Ashutosh Pathak, Boxiong Tang, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5618.
https://doi.org/10.1182/blood.V130.Suppl_1.5618.5618
Published: 2017
Journal Articles

Differences in Healthcare Utilization in CLL Patients Treated with BR Versus FCR

Susan Gabriel, Erika Szabo, Francesco Lo-Coco, Jifang Zhou, Boxiong Tang, Ashutosh Pathak
Journal: Blood
Blood (2016) 128 (22): 2406.
https://doi.org/10.1182/blood.V128.22.2406.2406
Published: 2016
Journal Articles

Budget Impact Analysis of Treating Chemotherapy Patients with Health Care Provider-Administered Tbo-Filgrastim, Filgrastim-Sndz, and Filgrastim in the United States

Holly Trautman, Erika Szabo, Francesco Lo-Coco, Elizabeth James, Susan Gabriel, Jifang Zhou, Ashutosh Pathak, Boxiong Tang
Journal: Blood
Blood (2016) 128 (22): 2407.
https://doi.org/10.1182/blood.V128.22.2407.2407
Published: 2016
Journal Articles

Budget Impact Analysis of Treating Chemotherapy Patients with Patient-Administered Tbo-Filgrastim, Filgrastim-Sndz, and Filgrastim in the United States

Holly Trautman, Erika Szabo, Francesco Lo-Coco, Elizabeth James, Susan Gabriel, Jifang Zhou, Ashutosh Pathak, Boxiong Tang
Journal: Blood
Blood (2016) 128 (22): 4786.
https://doi.org/10.1182/blood.V128.22.4786.4786
Published: 2016